Can a TKI Boost Anti-PD-L1 Activity in NSCLC?

Study reveals the advantages and pitfalls of adding a TKI to a monoclonal antibody after chemoradiation for non-small cell lung cancer. Medscape Medical News

Read the full article on medscape.com